Abstract 449P
Background
Improved cancer survival rates have escalated the demand for sustainable supportive care for survivors. Nasopharyngeal cancer (NPC) survivors often grapple with lasting radiation side effects. The M. D. Anderson Symptom Inventory - Head & Neck Module - Chinese version (MDASI-HN-C) has previously been validated for NPC patients undergoing radiation therapy (RT), but not for survivors. This study aims to psychometrically validate the MDASI-HN-C for NPC survivors.
Methods
In this single-centre cross-sectional study, 200 NPC survivors who completed RT with or without chemotherapy between three and 120 months were surveyed. The internal consistency reliability, convergent, and construct validity of the MDASI-HN-C were evaluated using Cronbach’s alpha (α) test, Pearson’s correlation (r), and exploratory factor analysis (EFA), respectively.
Results
All three subscales of the MDASI-HN-C exhibited strong internal consistency, with α ranging from 0.855 to 0.911. The MDASI-HN-C subscales were negatively correlated with the total score (r = -0.538 to -0.612; all p < 0.001), physical (r = -0.679 to -0.787; all p < 0.001), emotional (r = -0.536 to -0.625; all p < 0.001), functional (r = -0.307 to -0.390; all p < 0.001), and HN-specific (r = -0.587 to -0.616; all p < 0.001) domains of the Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN) scale. No correlations were identified between any subscales and the social/family domain. The MDASI-HN-C subscales were also positively correlated with the total score of the Cancer Survivors’ Unmet Needs Measure (CaSUN) (r = 0.414 to 0.468; all p < 0.001). Two factors for the 13 core items were identified by EFA, while only one factor each was found for the HN-specific and interference items. Noteworthily, open-ended responses indicated significant concerns about hearing loss and tinnitus among NPC survivors.
Conclusions
The MDASI-HN-C is a robust tool with satisfactory psychometric properties for assessing symptom burden among NPC survivors. The inclusion of 'hearing problems' as an additional item would enhance its applicability by capturing sensorial disturbances that significantly affect this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract